Spray drying technology for sustained release injectable PLGA formulation of drugs.
(Patent No. : KR0453273, KR0466637
Application No. : KR20030023130, JP20040187870
PCT : WO2005023224, WO2004112752)
With this technology, we have developed 1 and 3 month sustained release formulation of leuprolide acetate.
The final products show comparable in vivo efficacy with currently marketed products. This technology can be applied to develop other peptide based formulations.
Spray drying process with high production yield
Versatile release profiles from two weeks to several months
Controllable initial release
Easy, convenient and reproducible process
High encapsulation efficiency
Particle size can be easily controlled
Easy scale-up(Easy sterilization and cleaning)
No use of toxic organic solvents(e.g., methylene chloride, N-methylpyrrolidone, methanol)
 
 
 
Maintenance of protein stability
Biocompatible and bioabsorbable matrix
Controlled in vivo release profile
Complete release of protein
   
  SusTein™ Technology
  A preparation technology for solid protein-loaded microgranules which is continuously releasing proteins in vivo in the active state for several days.
(Patent No. : KR0452752
Application No. : US2003026844, EP1187602, US10/512.090
PCT : WO0178687, WO03094887
Trademark Resistration No. : 45-0008878000)
This technique is gleaned from nature's mechanism of stabilizing proteins by concentrating them in secretory granules and secreting them in soluble forms. SusTein™ formulation consists of two components, viz., condensed protein cores and encapsulating vehicle. Condensed protein cores are solid protein particles in which proteins are stabilized by complexation with sulfated polysaccharide at acidic pH. Condensed protein cores are coated with encapsulating vehicle, a sparingly water soluble matrix, which prevents burst release of protein and controls release rate of protein.
 
  SmartRod™ Technology
 
A preparation technology for a lipid implant which can continuously release protein in vivo as pharmaceutically active form after single subcutaneous injection.
(Patent No. : KR0486028
PCT : PCT/KR2005/001111
Trademark Registration No. :
40-05685480000)
Duration of in vivo release can be controlled in the range between several days to several months depending on the composition of lipids. In the SmartRod technique, we use biocompatible and bioabsorbable lipids as matrix components. Versatile in vivo release profiles with low initial release can be obtained by manipulating several essential manufacturing parameters. SmartRod™ is innovative technology in maintaining the stability of therapeutic proteins during manufacturing and in vivo releasing processes.